U.S. License Holder:
Regeneron Pharmaceuticals
Date of License:
February-11-2021
Last Update:
Sep-30-2025
FDA-Approved Indications
EVKEEZA (evinacumab-dgnb) is an angiopoietin-like 3 (ANGPTL3) inhibitor indicated as an adjunct to diet and exercise and other low-density lipoprotein-cholesterol (LDL-C) lowering therapies to reduce LDL-C in adults and pediatric patients, aged 1 year and older, with homozygous familial hypercholesterolemia (HoFH).